Table of Contents

company-logo

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Dividend Announcement

• REGENXBIO does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on REGENXBIO dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

REGENXBIO Dividend History

REGENXBIO Dividend Yield

REGENXBIO current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing REGENXBIO stock? Use our calculator to estimate your expected dividend yield:

REGENXBIO Financial Ratios

P/E ratio-2.46
PEG ratio0.56
P/B ratio1.95
ROE-70.65%
Payout ratio0.00%
Current ratio3.05
Quick ratio3.05
Cash Ratio0.55

REGENXBIO Dividend FAQ

Does REGENXBIO stock pay dividends?
REGENXBIO does not currently pay dividends to its shareholders.
Has REGENXBIO ever paid a dividend?
No, REGENXBIO has no a history of paying dividends to its shareholders. REGENXBIO is not known for its dividend payments.
Why doesn't REGENXBIO pay dividends?
There are several potential reasons why REGENXBIO would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will REGENXBIO ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While REGENXBIO has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is REGENXBIO a dividend aristocrat?
REGENXBIO is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is REGENXBIO a dividend king?
REGENXBIO is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is REGENXBIO a dividend stock?
No, REGENXBIO is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy REGENXBIO stocks?
To buy REGENXBIO you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy REGENXBIO stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.